• 66 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Review
    Interface between obesity with dysfunctional metabolism and inflammation, and the triple-negative breast cancer in African American women
    Obesity has dramatically increased over the past fifty years. In the last decade, it has been noted that augmented body mass, metabolic abnormalities, and the relevant “obese” [...] Read more.
    Katarzyna Rygiel
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:602-616
    DOI: https://doi.org/10.37349/etat.2021.00066
    This article belongs to the special issue Endocrine Resistant Breast Cancer
    View:143
    Download:25
    Times Cited: 0
    Open Access
    Original Article
    The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type
    Aim: Bromodomain and extra-terminal domain (BET) proteins are epigenetic readers that play a fundamental role in transcription regulation. Preclinical and early clinical evidence sustain BET targ [...] Read more.
    Chiara Tarantelli ... Francesco Bertoni
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:586-601
    DOI: https://doi.org/10.37349/etat.2021.00065
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:370
    Download:31
    Times Cited: 0
    Open Access
    Original Article
    Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
    Aim: Direct analytical comparison of two major drug-linkers in the antibody-drug conjugate (ADC) field was conducted. Methods: Four different analytical methods [AlogP calculation, reverse phase (RP) high-performance liquid chrom [...] Read more.
    Tomohiro Fujii ... Yutaka Matsuda
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:576-585
    DOI: https://doi.org/10.37349/etat.2021.00064
    This article belongs to the special issue Antibody-Drug Conjugates
    View:188
    Download:19
    Times Cited: 0
    Open Access
    Original Article
    Alterations in the Ca2+ toolkit in oesophageal adenocarcinoma
    Aim: To investigate alterations in transcription of genes, encoding Ca2+ toolkit proteins, in oesophageal adenocarcinoma (OAC) and to assess associations between gene expression, tumor  [...] Read more.
    Alana L. Cutliffe ... John J. Mackrill
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:543-575
    DOI: https://doi.org/10.37349/etat.2021.00063
    This article belongs to the special issue Calcium Signaling Apparatus in Cancers
    View:147
    Download:28
    Times Cited: 0
    Open Access
    Review
    Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
    The dismal prognosis of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) prompted recent advances in the field of therapeutic approaches beyond cytotoxic cancer therapy. In r [...] Read more.
    Stefano Cavalieri ... Laura D. Locati
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:522-542
    DOI: https://doi.org/10.37349/etat.2021.00062
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:234
    Download:39
    Times Cited: 0
    Open Access
    Review
    The clinical advances of proteolysis targeting chimeras in oncology
    Proteolysis targeting chimeras (PROTACs) are a class of small molecules designed to target proteins for degradation. Their novel and unique modes of action provide PROTACs with the potential for the [...] Read more.
    Hao Xie ... Jason B. Fleming
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:511-521
    DOI: https://doi.org/10.37349/etat.2021.00061
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:293
    Download:47
    Times Cited: 0
    Open Access
    Review
    Proteolysis-targeting chimeras and their implications in breast cancer
    Breast cancer (BC) is a highly heterogeneous neoplasm of the mammary tissue, causing the deaths of a large number of women worldwide. Nearly 70% and 20% of BC cases are estro [...] Read more.
    Angeles C. Tecalco-Cruz ... Alberto Rojas-Ochoa
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:496-510
    DOI: https://doi.org/10.37349/etat.2021.00060
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:273
    Download:38
    Times Cited: 0
    Open Access
    Review
    Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer
    Adjuvant hormonal therapy is one of the most important treatments of hormone-receptor-positive breast cancer and includes selective estrogen receptor modulators, aromatase inhibitors, and luteinizin [...] Read more.
    Alfredo Rossi ... Marta Carlesimo
    Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:490-495
    DOI: https://doi.org/10.37349/etat.2021.00059
    This article belongs to the special issue Endocrine Resistant Breast Cancer
    View:347
    Download:21
    Times Cited: 0
    Open Access
    Original Article
    Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center
    Aim: Since SARS-CoV-2 infection rapidly spread around the world, Italy has quickly become one of the most affected countries. Healthcare systems introduced strict infection control measures to ensu [...] Read more.
    Maristella Bungaro ... Silvia Novello
    Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:481-489
    DOI: https://doi.org/10.37349/etat.2021.00058
    This article belongs to the special issue COVID-19 and Cancer
    View:213
    Download:20
    Times Cited: 0
    Open Access
    Review
    Targeted therapy of multiple myeloma
    Multiple myeloma (MM) is a malignant proliferative disease of monoclonal plasma cells (PCs) and is characterized by uncontrolled proliferation of PCs and excessive production of specific types of im [...] Read more.
    Shan Zhou, Renxi Wang
    Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:465-480
    DOI: https://doi.org/10.37349/etat.2021.00057
    View:232
    Download:30
    Times Cited: 0
    Open Access
    Review
    A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
    Patients with unresectable biliary tract carcinomas (BTCs) have a poor prognosis with a median overall survival of fewer than 12 months following systemic chemotherapy. In recent years, the identifi [...] Read more.
    Giacomo Aimar ... Massimo Di Maio
    Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:448-464
    DOI: https://doi.org/10.37349/etat.2021.00056
    This article belongs to the special issue Precision Medicine for Cholangiocarcinoma
    Open Access
    Review
    Targeting protein kinase CK2 in the treatment of cholangiocarcinoma
    Cholangiocarcinoma (CCA) is a disease with a very poor prognosis and limited treatment options. Although targeted therapies directed towards specific mutations found in CCA are becoming available an [...] Read more.
    Padma-Sheela Jayaraman, Kevin Gaston
    Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:434-447
    DOI: https://doi.org/10.37349/etat.2021.00055
    This article belongs to the special issue Precision Medicine for Cholangiocarcinoma
    View:452
    Download:41
    Times Cited: 0
    Open Access
    Review
    Current options and future directions of systemic therapy for advanced biliary tract cancer
    Biliary tract cancers (BTCs) are aggressive tumors arising from different portions of the biliary tree and classified according to the anatomical location in intrahepatic (i) cholangiocarcinoma (CCA [...] Read more.
    Maria Giuseppina Prete ... Lorenza Rimassa
    Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:416-433
    DOI: https://doi.org/10.37349/etat.2021.00054
    This article belongs to the special issue Precision Medicine for Cholangiocarcinoma
    View:552
    Download:51
    Times Cited: 0
    Open Access
    Review
    A novel strategy for treating cancer: understanding the role of Ca2+ signaling from nociceptive TRP channels in regulating cancer progression
    Cancer is an aging-associated disease and caused by genomic instability that is driven by the accumulation of mutations and epimutations in the aging process. Although Ca2+ signaling, re [...] Read more.
    Wen-Li Hsu ... Etsuro Ito
    Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:401-415
    DOI: https://doi.org/10.37349/etat.2021.00053
    This article belongs to the special issue Calcium Signaling Apparatus in Cancers
    View:453
    Download:42
    Times Cited: 0
    Open Access
    Review
    Role of estrogen receptor coregulators in endocrine resistant breast cancer
    Breast cancer (BC) is the most ubiquitous cancer in women. Approximately 70–80% of BC diagnoses are positive for estrogen receptor (ER) alpha (ERα). The steroid ho [...] Read more.
    Kristin A. Altwegg, Ratna K. Vadlamudi
    Published: August 30, 2021 Explor Target Antitumor Ther. 2021;2:385-400
    DOI: https://doi.org/10.37349/etat.2021.00052
    This article belongs to the special issue Endocrine Resistant Breast Cancer
    View:935
    Download:62
    Times Cited: 0
    Open Access
    Review
    Does the gut microbiome environment influence response to systemic breast cancer treatment?
    The gut microbiome is a novel player in the pathogenesis and treatment of breast cancer. The term “microbiome” is used to describe the diverse community of micro-organisms exis [...] Read more.
    Eilidh Bruce ... Beatrix Elsberger
    Published: August 30, 2021 Explor Target Antitumor Ther. 2021;2:374-384
    DOI: https://doi.org/10.37349/etat.2021.00051
    View:393
    Download:23
    Times Cited: 0
    Open Access
    Review
    The evolving role and utility of off-label drug use in multiple myeloma
    The treatment landscape for multiple myeloma (MM) has dramatically changed over the last three decades, moving from no US Food and Drug Administration approvals and two active drug classes to over 1 [...] Read more.
    James H Stoeckle ... Gareth J Morgan
    Published: August 30, 2021 Explor Target Antitumor Ther. 2021;2:355-373
    DOI: https://doi.org/10.37349/etat.2021.00050
    This article belongs to the special issue Off-Label Drugs and -Omics Data in Cancer Treatment
    View:861
    Download:25
    Times Cited: 0
    Open Access
    Review
    The promising potential of piperlongumine as an emerging therapeutics for cancer
    In spite of the immense advancement in the diagnostic and treatment modalities, cancer continues to be one of the leading causes of mortality across the globe, responsible for the death of around 10 [...] Read more.
    Dey Parama ... Ajaikumar B. Kunnumakkara
    Published: August 30, 2021 Explor Target Antitumor Ther. 2021;2:323-354
    DOI: https://doi.org/10.37349/etat.2021.00049
    View:526
    Download:60
    Times Cited: 0
    Open Access
    Original Article
    The effect of iron on the expression levels of calcium related gene in cisplatin resistant epithelial ovarian cancer cells
    Aim: Anticancer drugs (chemotherapeutics) used in cancer treatment (chemotherapy) lead to drug resistance. This study was conducted to investigate the possible effect of iron on calcium homeostasis [...] Read more.
    Bahire Kucukkaya ... Leman Yalcintepe
    Published: August 30, 2021 Explor Target Antitumor Ther. 2021;2:309-322
    DOI: https://doi.org/10.37349/etat.2021.00048
    View:278
    Download:27
    Times Cited: 0
    Open Access
    Review
    Targeting cytoskeletal phosphorylation in cancer
    Phosphorylation of cytoskeletal proteins regulates the dynamics of polymerization, stability, and disassembly of the different types of cytoskeletal polymers. These control the ability of cells to m [...] Read more.
    Clara Llorente-González ... Miguel Vicente-Manzanares
    Published: June 28, 2021 Explor Target Antitumor Ther. 2021;2:292-308
    DOI: https://doi.org/10.37349/etat.2021.00047
    View:355
    Download:47
    Times Cited: 0
    Open Access
    Review
    Advances in the study of cancer metastasis and calcium signaling as potential therapeutic targets
    Metastasis is still the primary cause of cancer-related mortality. However, the underlying mechanisms of cancer metastasis are not yet fully understood. Currently, the epithelial-mesenchymal transit [...] Read more.
    Chaochu Cui ... Xianwei Wang
    Published: June 28, 2021 Explor Target Antitumor Ther. 2021;2:266-291
    DOI: https://doi.org/10.37349/etat.2021.00046
    This article belongs to the special issue Calcium Signaling Apparatus in Cancers
    View:637
    Download:84
    Times Cited: 0
    Open Access
    Review
    Overview of Ca2+ signaling in lung cancer progression and metastatic lung cancer with bone metastasis
    Intracellular Ca2+ ions that are thought to be one of the most important second messengers for cellular signaling, have a substantial diversity of roles in regulating a plethora of funda [...] Read more.
    Manh Tien Tran
    Published: June 28, 2021 Explor Target Antitumor Ther. 2021;2:249-265
    DOI: https://doi.org/10.37349/etat.2021.00045
    This article belongs to the special issue Calcium Signaling Apparatus in Cancers
    View:659
    Download:26
    Times Cited: 0
    Open Access
    Case Report
    Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type
    Lynch syndrome is a hereditary cancer predisposition syndrome caused by germline alterations in mismatch repair (MMR) genes leading to increased risk of colon cancer as well as other cancer types. N [...] Read more.
    Elena Maccaroni ... Rossana Berardi
    Published: June 28, 2021 Explor Target Antitumor Ther. 2021;2:240-248
    DOI: https://doi.org/10.37349/etat.2021.00044
    View:630
    Download:41
    Times Cited: 0
    Open Access
    Original Article
    Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis
    Aim: The role of tumor burden (TB) for patients with non-small cell lung cancer (NSCLC) receiving immunotherapy is still unknown. The aim of this analysis was to analyze the prognostic value of T [...] Read more.
    Edoardo Lenci ... Rossana Berardi
    Published: June 28, 2021 Explor Target Antitumor Ther. 2021;2:227-239
    DOI: https://doi.org/10.37349/etat.2021.00043
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:479
    Download:54
    Times Cited: 0
    Open Access
    Original Article
    Understanding doxorubicin associated calcium remodeling during triple-negative breast cancer treatment: an in silico study
    Aim: Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer with high heterogeneity, rapid progression, and paucity of treatment options. The most effective chemotherape [...] Read more.
    Garhima Arora ... Samrat Chatterjee
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:208-226
    DOI: https://doi.org/10.37349/etat.2021.00042
    This article belongs to the special issue Calcium Signaling Apparatus in Cancers
    View:822
    Download:74
    Times Cited: 0
    Open Access
    Editorial
    Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy?
    Carminia Maria Della Corte ... Floriana Morgillo
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:204-207
    DOI: https://doi.org/10.37349/etat.2021.00041
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:354
    Download:6
    Times Cited: 0
    Open Access
    Original Article
    Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors
    Aim: Nuclear factor erythroid 2-related factor 2 (NRF2) is a key component in the cell’s response to oxidative and electrophilic stress and is a transcription factor regulating the expre [...] Read more.
    Ibrahim H. Kankia ... Yusuf Y. Deeni
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:187-203
    DOI: https://doi.org/10.37349/etat.2021.00040
    View:456
    Download:41
    Times Cited: 0
    Open Access
    Review
    Gastrointestinal disorders as immune-related adverse events
    Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel dr [...] Read more.
    Daniele Balducci ... Luca Maroni
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:174-186
    DOI: https://doi.org/10.37349/etat.2021.00039
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:404
    Download:10
    Times Cited: 0
    Open Access
    Review
    Liquid biopsy in NSCLC: a new challenge in radiation therapy
    Lung cancer is the most common cancer and the leading cause of cancer mortality worldwide. To date, tissue biopsy has been the gold standard for the diagnosis and the identification of specific mole [...] Read more.
    Annarita Perillo ... Ida Rosalia Scognamiglio
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:156-173
    DOI: https://doi.org/10.37349/etat.2021.00038
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:582
    Download:24
    Times Cited: 0
    Open Access
    Review
    Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
    About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification [...] Read more.
    Paolo Tarantino ... Giuseppe Curigliano
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:139-155
    DOI: https://doi.org/10.37349/etat.2021.00037
    View:1728
    Download:89
    Times Cited: 0
    Open Access
    Review
    Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review
    Fungal compounds have long been used for centuries as food supplements. β-glucans have been identified as the most interesting molecules with beneficial effects in several chronic diseas [...] Read more.
    Valeria Cognigni ... Rossana Berardi
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:122-138
    DOI: https://doi.org/10.37349/etat.2021.00036
    This article belongs to the special issue Immunotherapy in Cancer Patients
    Open Access
    Review
    Aptamers and antibodies: rivals or allies in cancer targeted therapy?
    The goal of an efficacious cancer therapy is to specifically target diseased cells at high accuracy while sparing normal, healthy cells. Over the past three decades, immunotherapy, based on the use  [...] Read more.
    Lisa Agnello ... Laura Cerchia
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:107-121
    DOI: https://doi.org/10.37349/etat.2021.00035
    Open Access
    Review
    Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
    Multiple myeloma (MM), the second most common hematologic cancer, is caused by accumulation of aberrant plasma cells in the bone marrow. Its molecular causes are not fully understood and its great h [...] Read more.
    Sara Ovejero, Jerome Moreaux
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:65-106
    DOI: https://doi.org/10.37349/etat.2021.00034
    This article belongs to the special issue Off-Label Drugs and -Omics Data in Cancer Treatment
    View:1053
    Download:29
    Times Cited: 0
    Open Access
    Review
    Immunotherapy in gynecological cancers
    Immunotherapy has changed the natural history of several malignancies that, a decade ago, had a very poor prognosis, such as lung cancer and melanoma. Consequently, many attempts have been done to e [...] Read more.
    Domenica Lorusso ... Giovanni Scambia
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:48-64
    DOI: https://doi.org/10.37349/etat.2021.00033
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:627
    Download:26
    Times Cited: 0
    Open Access
    Review
    Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy
    The occurrence of phenotype switch from an epithelial to a mesenchymal cell state during the activation of the epithelial mesenchymal transition (EMT) program in cancer cells has been closely associ [...] Read more.
    Viviana De Rosa ... Francesca Iommelli
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:36-47
    DOI: https://doi.org/10.37349/etat.2021.00032
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:479
    Download:21
    Times Cited: 0
    Open Access
    Review
    Emerging role of pioneer transcription factors in targeted ERα positive breast cancer
    Transcription factors (TFs) are modular protein groups that preferably bind to DNA sequences and guide genomic expression through transcription. Among these key regulators, “pioneer facto [...] Read more.
    Honey Pavithran, Ranjith Kumavath
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:26-35
    DOI: https://doi.org/10.37349/etat.2021.00031
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:712
    Download:23
    Times Cited: 0
    Open Access
    Review
    Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
    The introduction of immune checkpoint inhibitors (ICIs) in non-oncogene addicted non-small cell lung cancer (NSCLC) has revolutionized the treatment scenario and led to a meaningful improvement in p [...] Read more.
    Luca Cantini ... Rossana Berardi
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:1-25
    DOI: https://doi.org/10.37349/etat.2021.00030
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:682
    Download:25
    Times Cited: 0
    Open Access
    Review
    An overview of immune checkpoint inhibitors in breast cancer
    Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-nega [...] Read more.
    Federica Miglietta ... Nicla La Verde
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:452-472
    DOI: https://doi.org/10.37349/etat.2020.00029
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:1578
    Download:72
    Open Access
    Review
    Circulating biomarkers in malignant pleural mesothelioma
    Malignant pleural mesothelioma (MPM) is an aggressive tumor strictly connected to asbestos exposure. Prognosis is dismal as diagnosis commonly occurs in advanced stage. Radiological screenings have  [...] Read more.
    Giuseppe Viscardi ... Giulia Galli
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:434-451
    DOI: https://doi.org/10.37349/etat.2020.00028
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:1091
    Download:37
    Open Access
    Letter to the Editor
    Is hyperprogressive disease a specific phenomenom of immunotherapy?
    Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particula [...] Read more.
    Marta Brambilla ... Mario Occhipinti
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:427-433
    DOI: https://doi.org/10.37349/etat.2020.00027
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:1018
    Download:20
    Times Cited: 0
    Open Access
    Review
    An overview of the potential anticancer properties of cardamonin
    Cancer is one of the leading causes of mortality, contributing to 9.6 million deaths globally in 2018 alone. Although several cancer treatments exist, they are often associated with severe side effe [...] Read more.
    Shanaya Ramchandani ... Manoj Garg
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:413-426
    DOI: https://doi.org/10.37349/etat.2020.00026
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    Open Access
    Review
    Targeting transcription factors in cancer drug discovery
    Cancer drug discovery is currently dominated by clinical trials or clinical research. Several potential drug candidates have been brought into the pipeline of drug discovery after showing very promi [...] Read more.
    Partha Mitra
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:401-412
    DOI: https://doi.org/10.37349/etat.2020.00025
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:1239
    Download:84
    Times Cited: 0
    Open Access
    Review
    Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
    Liquid biopsy has emerged as a minimally invasive alternative to tumor tissue analysis for the management of lung cancer patients, especially for epidermal growth factor receptor (EGFR) oncogene add [...] Read more.
    Marialucia Iacovino ... Francesca Sparano
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:391-400
    DOI: https://doi.org/10.37349/etat.2020.00024
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:890
    Download:32
    Times Cited: 0
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381-390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:1873
    Download:116
    Open Access
    Review
    Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer
    Cancer is one of the most dreadful diseases in the world with a mortality of 9.6 million annually. Despite the advances in diagnosis and treatment during the last couple of decades, it still remains [...] Read more.
    Sosmitha Girisa ... Ajaikumar B. Kunnumakkara
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:313-342
    DOI: https://doi.org/10.37349/etat.2020.00019
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    Open Access
    Case Report
    Pseudoprogression in lung cancer: a case report
    Immunotherapy dramatically changed the management of several malignancies including non-small cell lung cancer (NSCLC). Since immune checkpoint inhibitors have a different mechanism of action from c [...] Read more.
    Giulia Meoni ... Angela Stefania Ribecco
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:372-380
    DOI: https://doi.org/10.37349/etat.2020.00022
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:973
    Download:20
    Times Cited: 0
    Open Access
    Original Article
    Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer
    Aim: Tamoxifen (TAM) resistance remains a clinical issue in breast cancer. The authors previously reported that 15-hydroxyprostaglandin dehydrogenase (HPGD) was significantly downregulated in tamox [...] Read more.
    Milene Volpato ... Valerie Speirs
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:355-371
    DOI: https://doi.org/10.37349/etat.2020.00021
    View:1416
    Download:26
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273-312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:8957
    Download:1262
    Open Access
    Review
    Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers
    Lung cancer is still one of the main causes of cancer-related death, together with prostate and colorectal cancers in males and breast and colorectal cancers in females. The prognosis for non-small  [...] Read more.
    Giovanni Vicidomini ... Mario Santini
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:343-354
    DOI: https://doi.org/10.37349/etat.2020.00020
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:710
    Download:16
    Times Cited: 0
    Open Access
    Review
    Possible applications of salvianolic acid B against different cancers
    Cancer is the second death causing disease worldwide after cardiovascular abnormalities. The difficulty in treating tumor cells with more precise targeted interventions and recurrence of cancer afte [...] Read more.
    Iram Shahzadi ... Reza Mohammadinejad
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:218-238
    DOI: https://doi.org/10.37349/etat.2020.00014
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    Open Access
    Review
    PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
    BCL-XL is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-XL has also been identified [...] Read more.
    Peiyi Zhang ... Guangrong Zheng
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:259-272
    DOI: https://doi.org/10.37349/etat.2020.00017
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:2393
    Download:144
    Open Access
    Commentary
    Circulating cancer stem cells: an interesting niche to explore
    Federica Papaccio
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:253-258
    DOI: https://doi.org/10.37349/etat.2020.00016
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:1036
    Download:37
    Open Access
    Review
    Future directions and management of liquid biopsy in non-small cell lung cancer
    Lung cancer represents the world’s most common cause of cancer death. In recent years, we moved from a generic therapeutic strategy to a personalized approach, based on the molecular char [...] Read more.
    Alessia Maria Cossu ... Marco Bocchetti
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:239-252
    DOI: https://doi.org/10.37349/etat.2020.00015
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:1237
    Download:32
    Times Cited: 0
    Open Access
    Review
    A brief overview of antitumoral actions of bruceine D
    Cancer remains the second leading cause of mortality globally. In combating cancer, conventional chemotherapy and/or radiotherapy are administered as first-line therapy. However, these are usually a [...] Read more.
    Zi Wayne Sin ... Manoj Garg
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:200-217
    DOI: https://doi.org/10.37349/etat.2020.00013
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:1149
    Download:35
    Open Access
    Review
    Role of liquid biopsy for thoracic cancers immunotherapy
    Immunotherapy has shifted the therapeutic landscape in thoracic cancers. However, assessment of biomarkers for patient selection and disease monitoring remain challenging, especially considering the [...] Read more.
    Raimondo Di Liello ... Paloma Martín-Martorell
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:183-199
    DOI: https://doi.org/10.37349/etat.2020.00012
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:1577
    Download:29
    Open Access
    Review
    Integration of PARP-inhibitors in ovarian cancer therapy
    Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. [...] Read more.
    Antonella Pietragalla ... Gennaro Daniele
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:171-182
    DOI: https://doi.org/10.37349/etat.2020.00011
    Open Access
    Review
    An overview of the anti-cancer actions of Tanshinones, derived from Salvia miltiorrhiza (Danshen)
    Tanshinone is a herbal medicinal compound described in Chinese medicine, extracted from the roots of Salvia miltiorrhiza (Danshen). This family of compounds, including Tanshinone IIA and Tanshinone [...] Read more.
    Irum Naz ... Kwang Seok Ahn
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:153-170
    DOI: https://doi.org/10.37349/etat.2020.00010
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:1653
    Download:56
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell  [...] Read more.
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131-152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:4558
    Download:185
    Open Access
    Review
    Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
    Several preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advance [...] Read more.
    Giuliano Palumbo ... Alessandro Morabito
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:117-130
    DOI: https://doi.org/10.37349/etat.2020.00008
    View:1081
    Download:32
    Times Cited: 0
    Open Access
    Case Report
    Multiple adverse drug reactions during all-trans retinoic acid treatment for acute promyelocytic leukemia: differentiation syndrome, bradycardia, intestinal necrosis
    All-trans retinoic acid (ATRA) induces complete remission in a high proportion of acute promyelocytic leukemia (APL). Nevertheless it is be associated with adverse drug reactions that might be life- [...] Read more.
    Valeria Ferla ... Nicola Stefano Fracchiolla
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:109-116
    DOI: https://doi.org/10.37349/etat.2020.00007
    View:1050
    Download:9
    Times Cited: 0
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71-100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:6699
    Download:367
    Open Access
    Original Article
    Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients
    Aim: Single biomarker diagnostic test of BRAFV600 locus in metastatic melanoma is mandatory for treatment decision; however, multiple-gene based techniques, such as targeted next-generation sequenc  [...] Read more.
    Paola Castillo ... Cristina Teixido
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:101-108
    DOI: https://doi.org/10.37349/etat.2020.00006
    View:1217
    Download:27
    Open Access
    Review
    Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma
    Colorectal carcinoma (CRC) is an heterogeneous disease in which different genetic alterations play a role in its pathogenesis and progression and offer potential for therapeutic intervention. The re [...] Read more.
    Anna Maria Rachiglio ... Nicola Normanno
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:53-70
    DOI: https://doi.org/10.37349/etat.2020.00004
    View:2952
    Download:102
    Open Access
    Review
    Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer
    The Fanconi anaemia (FA) pathway is an important mechanism for cellular DNA damage repair, which functions to remove toxic DNA interstrand crosslinks. This is particularly relevant in the context of [...] Read more.
    Sarah J Taylor ... Simon P Langdon
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:26-52
    DOI: https://doi.org/10.37349/etat.2020.00003
    View:3283
    Download:98
    Times Cited: 0
    Open Access
    Review
    Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms
    Cancer development is frequently associated with dysregulation of mRNA translation to enhance both increased global protein synthesis and translation of specific mRNAs encoding oncoproteins. Thus, t [...] Read more.
    Joe Taylor ... Graham Packham
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:3-25
    DOI: https://doi.org/10.37349/etat.2020.00002
    View:3264
    Download:91
    Open Access
    Editorial
    Exploration of Targeted Anti-tumor Therapy: a contribution to the development of targeted therapies
    Nicola Normanno, Graham Packham
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:1-2
    DOI: https://doi.org/10.37349/etat.2020.00001
    View:553
    Download:7
    Times Cited: 0